Ferring, Aventis Reach $20M Deal In DDAVP Antitrust Suit

Law360, New York (August 4, 2011, 3:50 PM EDT) -- Ferring BV and Aventis Pharmaceuticals Inc. on Wednesday agreed to pay $20.25 million to settle with a proposed class of direct purchasers of DDAVP who claimed in a New York suit that the companies suppressed generic competition by fraudulently acquiring a patent for the diabetes drug.

Attorneys for the proposed class sought preliminary approval of a deal that calls for Ferring to shell out $16.75 million and Aventis to cough up $3.5 million to resolve allegations that the companies violated the Sherman Act.

The lawsuit, filed...
To view the full article, register now.